Lung Cancer
Conditions
Interventions
Treatment Group:Furmonertinib 80mg,qd,8 weeks
Sponsors
West China School of Medicine/West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed as operable stage IIIA (T3N1, T4N0-1) NSCLC; 2. Patients who are planned to receive neoadjuvant targeted therapy; 3. Have previous biopsy/surgical collected tissue specimens, which are used for NGS panel detection and show EGFR L858R or exon19 del mutations; 4. Age 18 - 75 years old, regardless of gender; 5. ECOG score 0 - 2; 6. Understand and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Diagnosed with other malignant tumors before enrollment (excluding in situ carcinoma that was resected 5 years ago before enrollment); 2. Had allogeneic blood transfusion within 30 days before enrollment; 3. Had a history of allogeneic organ transplantation or bone marrow transplantation; 4. Pregnant or lactating women; 5. Any other situation where the investigator considers the patient not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major pathological response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathological complete response rate;Events Free Survival; | — |
Countries
China
Contacts
Public ContactGuowei Che
West China School of Medicine/West China Hospital of Sichuan University
Outcome results
None listed